The primary objective is to evaluate the efficacy of high and low doses of lumateperone vs placebo for the treatment of irritability associated with autism spectrum disorder (ASD) in pediatric patients as measured by the change from baseline to end of Week 6 in the ABC Irritability (ABC-I) subscale score.
